Comparative Pharmacology
Head-to-head clinical analysis: VALBENAZINE versus XENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALBENAZINE versus XENAZINE.
VALBENAZINE vs XENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing dopamine release in the striatum.
Deutetrabenazine selectively and reversibly inhibits vesicular monoamine transporter 2 (VMAT2), thereby reducing dopamine and monoamine storage and release in presynaptic neurons.
50 mg orally once daily; can be increased to 75 mg orally once daily based on tolerability and response.
12.5 mg orally twice daily initially; titrate slowly by 12.5 mg every 3-5 days up to 50 mg twice daily (total daily dose 100 mg). Maximum recommended total daily dose: 100 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 17-23 hours, allowing for once-daily dosing.
Clinical Note
moderateValbenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Cyclosporine
7-16 hours (mean 9-12 hours); requires twice-daily dosing for steady-state control of chorea.
Primarily hepatic metabolism; less than 30% of the dose excreted unchanged in urine and feces combined. Biliary/fecal excretion accounts for approximately 40-60% as metabolites.
Primarily renal (75-85% as metabolites, <2% unchanged); minimal biliary/fecal elimination.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Valbenazine."